Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons. Its portfolio includes orthobiologics for bone healing as well as spinal implants and instrumentation, sold primarily in the United States and also through international distribution channels.

9,3 %

62,9 %

3,7 %

+14,2 %

2.65

1.63

— Xtant Medical Holdings, Inc.
%
Orthobiologics55% Biologic products used to support bone growth and healing in spine and orthopedic procedures.
Spine hardware and instrumentation35% Implants, fixation systems, and surgical instrumentation used in spinal disease treatment.
Allografts and regenerative tissue products10% Human tissue-based products including bone matrices and amniotic membrane allografts.

Xtant sells to orthopedic and neurological surgeons through independent distributors, stocking agents, and direct...

  • Orthopedic surgeonsprimary

    Buy orthobiologics and graft products to support bone healing in surgical procedures.

  • Neurological and spine surgeonsprimary

    Buy spinal implants, fixation systems, and instrumentation for spine surgery.

  • Independent distributors and stocking agentsprimary

    Purchase and place products into accounts, helping drive surgeon adoption and hospital access.

  • IDNs and GPOssecondary

    Provide purchasing access and contracting leverage for hospitals and surgical networks.

  • International stocking partnerssecondary

    Distribute products in Europe, Canada, Mexico, South America, Australia, and Pacific markets.

The company is centered on the United States, where it sells through independent agents, stocking distributors, and...

  • •United States is the core commercial market
  • •Sales access includes IDNs and GPOs across the U.S.
  • •International sales run through direct reps and stocking partners
  • •Europe, Canada, Mexico, South America, Australia, and Pacific regions are served
  • •Geographic breadth supports growth but increases regulatory and channel complexity

Xtant is focused on expanding its product portfolio, broadening distribution, and entering adjacent markets around...

01
New product introductionsshort-term

Fresh products help defend surgeon relationships and expand use cases in spine and orthobiologics.

02
Distribution expansionshort-term

A broader channel footprint improves access to hospitals, surgeons, and regional accounts.

03
Adjacent market penetrationmedium-term

Moving into related surgical categories can increase wallet share with existing customers.

04
Strategic transactions and acquisitionsmedium-term

Deals can add products, technology, or distribution reach without building everything internally.

Xtant faces execution risk from product launches, channel dependence, and the complexity of selling through...

high

Pending sale of Coflex/CoFix and international hardware business

The transactions may be delayed, fail to close, or distract management and disrupt customers and suppliers.

Scope
Core business relationships and operating continuity
Materiality
high
high

Need for additional financing

The company may require capital before expected cash resources are exhausted, and terms may be unfavorable.

Scope
Liquidity and strategic flexibility
Materiality
high
medium

Channel concentration and distributor dependence

Sales rely heavily on independent agents and stocking distributors, which can affect coverage and pricing control.

Scope
U.S. commercial execution
Materiality
high
medium

Product adoption and launch risk

New biologics and spine systems must gain surgeon acceptance and hospital access to scale.

Scope
Trivium, Cortera, SimpliGraft, SimpliMax
Materiality
medium
medium

Regulatory and reimbursement pressure

Medical device and biologics businesses depend on approvals, compliance, and payer acceptance.

Scope
Spine and regenerative medicine markets
Materiality
high
Revenue recognition
Affects quarterly revenue timing and comparability
Transaction accounting
Can materially affect reported operating results
Debt and interest expense
Affects net income and liquidity analysis
Impairment and valuation
Could create non-cash charges to earnings

MIMEDX GROUP, INC.

MDXG · Surgical & Medical Instruments & Apparatus

Axogen, Inc.

AXGN · Electromedical & Electrotherapeutic Apparatus

Organogenesis Holdings Inc.

ORGO · Pharmaceutical Preparations

Regenerative Medical Technology Group Inc.

RMTG · Retail-Retail Stores, NEC

INTEGRA LIFESCIENCES HOLDINGS CORP

IART · Surgical & Medical Instruments & Apparatus

ZIMMER BIOMET HOLDINGS, INC.

ZBH · Orthopedic, Prosthetic & Surgical Appliances & Supplies

: 29/04/2026